Aim: There have been few studies since the beginning of the pandemic researching thehistopathologies and conducting molecular investigations of the placentas of SARS-CoV-2positive pregnant women. The aim of this study was to analyze the changes in theexpression of angiogenic growth factors in the placentas of pregnant women infected withSARS-CoV-2 (the COVID-19 group), and to make comparisons with the placentas ofnon-infected pregnant women (the control group).Methods: Placentas taken at birth from 20 healthy women (control) and 20 women with apositive test for COVID-19 were prepared for histopathological examination.Immunohistochemical staining was applied in placental tissues with ACE2(Angiotensin-conversion enzyme-2), VEGF (Vascular Endothelial Growth Factor), VEGFR-1(Vascular Endothelial Growth Factor Receptor 1) and PDGF (Platelet-Derived GrowthFactor).Results: First, the presence of COVID-19 in the placental tissue was assessed by the ACE2immunohistochemical method. It was seen that ACE2 was expressed weakly in the placentalsyncytiotrophoblast cells of non-infected women, but in the syncytiotrophoblasts of theplacentas of women infected with COVID-19, ACE2 expression was much higher. VEGF in theendothelial and stromal cells of the villi of the control group was very strong, but inthe villi of infected placentas it was significantly weaker. VEGFR-1 was positive in theendothelial membranes of the villi of the control group, but was significantly weaker inthe villi of infected placentas. PDGF expression was strong in the syncytiotrophoblastand stromal cells of the control group, but was significantly noticeably weaker inCOVID-19 positive placentas.